Last reviewed · How we verify

Talazoparib plus Irinotecan

QuantumLeap Healthcare Collaborative · Phase 2 active Small molecule

Talazoparib plus Irinotecan is a Small molecule drug developed by QuantumLeap Healthcare Collaborative. It is currently in Phase 2 development.

At a glance

Generic nameTalazoparib plus Irinotecan
SponsorQuantumLeap Healthcare Collaborative
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Talazoparib plus Irinotecan

What is Talazoparib plus Irinotecan?

Talazoparib plus Irinotecan is a Small molecule drug developed by QuantumLeap Healthcare Collaborative.

Who makes Talazoparib plus Irinotecan?

Talazoparib plus Irinotecan is developed by QuantumLeap Healthcare Collaborative (see full QuantumLeap Healthcare Collaborative pipeline at /company/quantumleap-healthcare-collaborative).

What development phase is Talazoparib plus Irinotecan in?

Talazoparib plus Irinotecan is in Phase 2.

Related